Organon & Co. (NYSE:OGN) Shares Purchased by Amundi

Amundi increased its stake in Organon & Co. (NYSE:OGN - Free Report) by 37.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 616,390 shares of the company's stock after acquiring an additional 167,553 shares during the period. Amundi owned approximately 0.24% of Organon & Co. worth $9,860,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Commerce Bank increased its holdings in Organon & Co. by 5.5% in the third quarter. Commerce Bank now owns 12,168 shares of the company's stock valued at $233,000 after buying an additional 637 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after buying an additional 672 shares during the last quarter. Beam Wealth Advisors Inc. increased its holdings in Organon & Co. by 3.9% in the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company's stock valued at $282,000 after buying an additional 717 shares during the last quarter. CIBC Asset Management Inc increased its holdings in Organon & Co. by 4.9% in the fourth quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock valued at $381,000 after buying an additional 1,184 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its holdings in Organon & Co. by 24.3% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company's stock valued at $93,000 after buying an additional 1,222 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Organon & Co. Stock Performance

Shares of NYSE OGN traded up $0.08 during midday trading on Tuesday, reaching $15.70. 2,333,910 shares of the company were exchanged, compared to its average volume of 2,340,553. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock has a fifty day simple moving average of $15.46 and a 200 day simple moving average of $16.60. The stock has a market cap of $4.05 billion, a P/E ratio of 4.71, a PEG ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. On average, research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.14%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is currently 33.63%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Morgan Stanley dropped their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday, February 14th. Barclays dropped their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.